Ten in a Million! SVision Won the Top Ten in the Asia Pacific Ophthalmology Big Data Competition!

In mid-January, the 2021 Asia Pacific Society of Ophthalmology Big Data Competition on Tianchi Platform, which lasted for more than 3 months, came to an end. The SVision’s algorithm team composed of Dr. Zhilin Wu, director of algorithms and algorithm engineer Dandan Huang stood out from tens of thousands of participating teams. They only spent more than ten days preparing for the competition while ensuring normal R & D work. Finally, they entered the finals and won the tenth place. They were shortlisted in the top ten together with top AI research groups such as Tsinghua University and Xi’an University of Electronic Science and technology.

Asia-Pacific Ophthalmology Big Data Competition Ranking

This time, through short-term preparation, SVision made great achievements in this competition, which gathers top AI teams in the field of ophthalmology, proving its strong AI technology strength to the world. Meanwhile, the world’s leading AI algorithm used in the competition will also drive the product update and iteration, so as to better serve global users.

The award certificate of the SVision algorithm team

The competition was organized by The Asia Pacific Society of Ophthalmology (APTOS), co-organized by Rajavi Hospital in Thailand, Aravind Eye Hospital in India and Zhongshan Eye Center of Sun Yat-sen University in China. Ali Yuntianchi Platform provided exclusive technical support for the competition. The theme of the competition is to predict the outcome of anti-VEGF anti-vascular endothelial growth factor (ANTI-VEGF) therapy in patients with diabetic macular edema (DME). The judges included technical guests from Asia Pacific Society of Ophthalmology, Aliyun and other medical ophthalmology industry professionals.

In this regard, Dr. Zhilin Wu, one of the winners of the SVision algorithm team, said that for the theme of the competition, he and his participating partners carried out deep learning, artificial intelligence and image analysis within a limited time of more than ten days without affecting the normal R&D work. The research and development of the algorithm was finally shortlisted in the top ten, which is inseparable from the long-term and solid accumulation of AI technology of SVision itself and the directional guidance provided by the professional ophthalmic medical talents of SVision.

Dr.Zhilin Wu received his Ph.D. in Electrical and Computer Engineering from Northwestern University in 2004. He has more than 20 years of research and work experience in data science and analysis. He has published more than 50 papers in international academic journals and conferences, and holds 10 patents. Now He is a guest researcher of Shanghai University of Science and Technology. He particularly pointed out that a large number of advanced AI algorithms were incorporated into the original SVision OCT products, and during this competition, they were updated and upgraded on the basis of the previous ones. Through the fusion of improved deep learning models and advanced data analysis algorithms, it further improves the accuracy of image segmentation and data prediction, and enhances the adaptability to various ocular disease characteristics. In addition, the efficiency of the algorithm is especially strengthened, which makes the research more practical. In the future, it is hoped that these brand-new algorithms will be applied to more equipment and products of SVision to identify pathological features in scanned images more efficiently and quickly, help ophthalmologists diagnose various diseases, and improve the efficiency of clinical diagnosis and treatment to a greater extent.

SVision AI algorithm segmentation

SVision AI lesion identification

In recent years, AI artificial intelligence has been applied to different technical fields and is becoming an important driving force for a new round of technological revolution and industrial transformation. In the field of ophthalmology, the use of AI technology to judge fundus images can quickly screen fundus diseases, so as to achieve early screening, early prevention, and early treatment, which is an epoch-making technological innovation.

As a leader in domestic high-end ophthalmic equipment, SVision is the first to carry artificial intelligence on its first self-developed swept-source OCTA equipment in China, and incorporates a large number of advanced AI-based algorithms, including AI-based retinal 3D recognition algorithm, anterior segment 3D recognition Algorithms, 3D recognition algorithms for choroid and choroidal vascular, and 3D recognition algorithms for subretinal effusions, AI empowerment further improves the intelligence, precision and clarity of OCTA products. At present, SVision’s first self-developed OCT product is ahead of imported high-end products in imaging quality, range, depth, speed, and Angiography algorithm, created a precedent for domestic high-end ophthalmic equipment to surpass imports.

The powerful AI-driven attributes made SVision selected as “China’s Top 50 Medical Artificial Intelligence” by “Internet Weekly” for two consecutive years in 2018 and 2019. In 2019, SVision OCT products were certified by the national NMPA and were recognized as “internationally advanced” by the Ministry of Science and Technology in 2021. CCTV and Xinhua News Agency reported that SVision OCT products “new technologies lead the big health industry into the intelligent era”.

SVision was founded in Silicon Valley in 2014 by three US-educated PhDs, which are Xianzhao Peng , Bing Li and Zhengyu Wang. World-class R&D team with experience in semiconductor optics and high-end medical equipment development. The three founders of SVision and a number of core R&D members, including Dr. Zhilin Wu, lead the precision optics and hardware system team, artificial intelligence and advanced algorithm team respectively, injecting key genes into the company: the world’s top software and hardware technology + world leading domestic high-end ophthalmic equipment powered by AI algorithms.

In the future, based on core technologies such as advanced AI algorithms, high-performance computing, and precision optical imaging, SVision will also develop diagnostic-grade artificial intelligence products that far exceed the recognition performance of fundus color photos, including whole-eye OCT products, ultra-widefield fundus cameras, and microscope OCT, providing powerful diagnosis and treatment tools for ophthalmologists. At the same time, SVision will continue to expand its overseas team, upgrade its U.S. R&D operation center, set up a European R&D operation center in Germany, expand globally and enter the core markets of Europe and the United States. Striving to become a global leader in high-end ophthalmic medical devices — “Ophthalmic Tesla”.